The LY3127804 Study

- A phase-2 clinical trial assessing the efficacy of LY3127804 a monoclonal antibody targeting angiopoietin-II.
- This study focuses on a patient population hospitalized with pneumonia or presumed/confirmed COVID-19 infections.
- The primary outcome measure assessed by this study is number of ventilator free days for patients suffering from ARDS with presumed/confirmed COVID-19 infections.

The Disrupt Study

- A phase-3 clinical trial assessing the efficacy of Execbacase study drug in conjunction with standard antibiotic treatment regimens.
- The patient population in question for this study are those with Staphylococcus Aureus bacteremia and endocarditis.
- For this study, I was responsible for screening potential subjects based on inclusion/exclusion study criteria.
- For more information regarding the Disrupt study please visit clinicaltrials.gov.

REFERENCES


ClinicalTrials.gov


ACKNOWLEDGEMENTS

I would like to thank both Jamie Wigent and Dr. Paul Cook for the opportunity to be a part of the research department at ECU Adult Specialty Care Clinic. They have been influential mentors throughout my SSRP learning experience.